Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer.
Acute myeloid leukemia
Breast cancer
G-CSF
Lung cancer
Myelodysplastic syndromes
Prostate cancer
Safety
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
01
02
2022
accepted:
17
03
2022
pubmed:
18
4
2022
medline:
25
5
2022
entrez:
17
4
2022
Statut:
ppublish
Résumé
Patients diagnosed with cancer have an increased risk both for myelodysplastic syndromes (MDS) and for acute myeloid leukemia (AML) following treatment. Using SEER-Medicare data, we selected patients aged 66 years and older who completed systemic therapy between 2002 and 2014 for breast (stage I-III), lung (stage I-III), or prostate (stage I-IV) cancer. For each cancer, we estimated the risk of a composite endpoint of MDS or AML in patients receiving granulocyte colony-stimulating factor (G-CSF) vs. not. The 10-year cumulative risk difference (granulocyte colony-stimulating factor [G-CSF] - no G-CSF) for MDS-AML was 0.45% (95% CI 0.13-0.77%) in breast cancer and 0.39% (95% CI 0.15-0.62%) in lung cancer. G-CSF use was associated with a hazard ratio of 1.60 (95% CI 1.07-2.40) in breast cancer and 1.50 (95% CI 0.99-2.29) in lung cancer. Filgrastim use was associated with a hazard ratio of 1.01 (95% CI 1.00-1.03) per administration in breast cancer and 1.02 (95% CI 0.99-1.05) per administration in lung cancer. Pegfilgrastim was associated with a hazard ratio of 1.08 (95% CI 1.01-1.15) per administration in breast cancer and 1.12 (95% CI 1.00-1.25) per administration in lung cancer. Analyses in prostate cancer were limited because of the low number of events. The use of G-CSF in patients diagnosed with breast and lung cancer is associated with an increased risk of MDS-AML. However, the MDS-AML absolute risk difference is very low.
Identifiants
pubmed: 35430673
doi: 10.1007/s12325-022-02141-1
pii: 10.1007/s12325-022-02141-1
doi:
Substances chimiques
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2778-2795Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914–24. https://doi.org/10.1200/JCO.2009.25.8723 .
doi: 10.1200/JCO.2009.25.8723
pubmed: 20385991
Calip GS, Malmgren JA, Lee WJ, Schwartz SM, Kaplan HG. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer. Breast Cancer Res Treat. 2015;154(1):133–43. https://doi.org/10.1007/s10549-015-3590-1 .
doi: 10.1007/s10549-015-3590-1
pubmed: 26450505
pmcid: 4718738
Castro GA, Church A, Pechet L, Snyder LM. Leukemia after chemotherapy of Hodgkin’s disease. N Engl J Med. 1973;289(2):103–4. https://doi.org/10.1056/nejm197307122890215 .
doi: 10.1056/nejm197307122890215
pubmed: 4513796
Preisler HD, Lyman GH. Acute myelogenous leukemia subsequent to therapy for a different neoplasm: clinical features and response to therapy. Am J Hematol. 1977;3(3):209–18. https://doi.org/10.1002/ajh.2830030301 .
doi: 10.1002/ajh.2830030301
pubmed: 341697
Kaplan HG, Malmgren JA, Atwood MK. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990–2005. BMC Cancer. 2011;11:260. https://doi.org/10.1186/1471-2407-11-260 .
doi: 10.1186/1471-2407-11-260
pubmed: 21693006
pmcid: 3141775
Larson RA. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007;20(1):29–37. https://doi.org/10.1016/j.beha.2006.10.006 .
doi: 10.1016/j.beha.2006.10.006
pubmed: 17336252
Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(4):418–29. https://doi.org/10.1053/j.seminoncol.2008.04.012 .
doi: 10.1053/j.seminoncol.2008.04.012
pubmed: 18692692
pmcid: 2600445
Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23(18):4179–91. https://doi.org/10.1200/JCO.2005.05.029 .
doi: 10.1200/JCO.2005.05.029
pubmed: 15961765
Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol. 2003;21(7):1195–204. https://doi.org/10.1200/JCO.2003.03.114 .
doi: 10.1200/JCO.2003.03.114
pubmed: 12663705
Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol. 2007;25(25):3871–6. https://doi.org/10.1200/JCO.2007.12.0832 .
doi: 10.1200/JCO.2007.12.0832
pubmed: 17664457
Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D. Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin. 2017;33(12):2107–13. https://doi.org/10.1080/03007995.2017.1386858 .
doi: 10.1080/03007995.2017.1386858
pubmed: 28958157
Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst. 2007;99(3):183–6. https://doi.org/10.1093/jnci/djk057 .
doi: 10.1093/jnci/djk057
pubmed: 17284707
Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating–factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333(8):487–93. https://doi.org/10.1056/NEJM199508243330804 .
doi: 10.1056/NEJM199508243330804
pubmed: 7542747
Voso MT, Falconi G, Fabiani E. What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood. 2021;138(9):749–57. https://doi.org/10.1182/blood.2021010764 .
doi: 10.1182/blood.2021010764
pubmed: 33876223
Pich O, Cortes-Bullich A, Muiños F, Pratcorona M, Gonzalez-Perez A, Lopez-Bigas N. The evolution of hematopoietic cells under cancer therapy. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-24858-3 .
doi: 10.1038/s41467-021-24858-3
pubmed: 34376657
pmcid: 8355079
Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3):196–205. https://doi.org/10.1093/jnci/djk028 .
doi: 10.1093/jnci/djk028
pubmed: 17284714
Food and Drug Administration. Filgrastim [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103353s5183lbl.pdf . Accessed 13 June 2018.
Food and Drug Administration. Pegfilgrastim [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125031s180lbl.pdf . Accessed 13 June 2018.
Molineux G, Foote MA, Arvedson T. Twenty years of G-CSF: clinical and nonclinical discoveries. Basel: Springer; 2012.
doi: 10.1007/978-3-0348-0218-5
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. https://doi.org/10.3322/caac.21332 .
doi: 10.3322/caac.21332
pubmed: 26742998
Wang L, Barron R, Baser O, Langeberg WJ, Dale DC. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. Value Health. 2014;17(6):739–43. https://doi.org/10.1016/j.jval.2014.06.009 .
doi: 10.1016/j.jval.2014.06.009
pubmed: 25236998
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. https://doi.org/10.1016/j.ejca.2018.07.005 .
doi: 10.1016/j.ejca.2018.07.005
pubmed: 30100160
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med care. 2002;40(8 Suppl):IV-3–18. https://doi.org/10.1097/01.MLR.0000020942.47004.03 .
doi: 10.1097/01.MLR.0000020942.47004.03
Enewold L, Parsons H, Zhao L, et al. Updated overview of the SEER-medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020(55):3–13. https://doi.org/10.1093/jncimonographs/lgz029 .
doi: 10.1093/jncimonographs/lgz029
pubmed: 32412076
pmcid: 7225666
Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–9. https://doi.org/10.1093/aje/kwm324 .
doi: 10.1093/aje/kwm324
pubmed: 18056625
Sargramostim Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103362s5240lbl.pdf . Accessed 15 Feb 2021
National Cancer Institute. Observational Research in Oncology Toolbox. https://seer.cancer.gov/oncologytoolbox/ . Accessed 17 Oct 2019.
Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54(9):e55-64. https://doi.org/10.1097/MLR.0000000000000073 .
doi: 10.1097/MLR.0000000000000073
pubmed: 24638121
pmcid: 4981219
Paravati AJ, Boero IJ, Triplett DP, et al. Variation in the cost of radiation therapy among medicare patients with cancer. J Oncol Pract. 2015;11(5):403–9. https://doi.org/10.1200/jop.2015.005694 .
doi: 10.1200/jop.2015.005694
pubmed: 26265172
pmcid: 4575405
Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and breast cancer survival in the United States. JAMA Oncol. 2016;2(3):330–9. https://doi.org/10.1001/jamaoncol.2015.4508 .
doi: 10.1001/jamaoncol.2015.4508
pubmed: 26659430
pmcid: 4788555
Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, et al. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: a SEER-Medicare investigation. Cancer Med. 2019;8(6):3325–35. https://doi.org/10.1002/cam4.2092 .
doi: 10.1002/cam4.2092
pubmed: 31094098
pmcid: 6558501
Nadpara PA, Madhavan SS, Tworek C. Disparities in lung cancer care and outcomes among elderly in a medically underserved state population—a cancer registry-linked database study. Popul Health Manag. 2016;19(2):109–19. https://doi.org/10.1089/pop.2015.0027 .
doi: 10.1089/pop.2015.0027
pubmed: 26086239
pmcid: 4939453
Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584–90. https://doi.org/10.1016/j.annepidem.2007.03.011 .
doi: 10.1016/j.annepidem.2007.03.011
pubmed: 17531502
Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–5. https://doi.org/10.1182/blood-2011-02-337964 .
doi: 10.1182/blood-2011-02-337964
pubmed: 21531980
pmcid: 3143554
Craig BM, Rollison DE, List AF, Cogle CR. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol Biomark Prev. 2012;21(3):474–81. https://doi.org/10.1158/1055-9965.EPI-11-1087 .
doi: 10.1158/1055-9965.EPI-11-1087
Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56. https://doi.org/10.1093/aje/kwp107 .
doi: 10.1093/aje/kwp107
pubmed: 19494242
pmcid: 2732996
Comprehensive R Archive Network. Vienna: R Foundation for Statistical Computing.
Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer. 2013;13:11. https://doi.org/10.1186/1471-2407-13-11 .
doi: 10.1186/1471-2407-13-11
pubmed: 23298389
pmcid: 3559272
Gawade PL, Li S, Henry D, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Supportive Care Cancer. 2020. https://doi.org/10.1007/s00520-020-05295-2 .
doi: 10.1007/s00520-020-05295-2
Westreich D, Greenland S. The Table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177(4):292–8. https://doi.org/10.1093/aje/kws412 .
doi: 10.1093/aje/kws412
pubmed: 23371353
pmcid: 3626058